1 results match your criteria: "Infermi Hospital of Biella[Affiliation]"
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
Oncol Rep
February 2023
Department of Medical Oncology, Infermi Hospital of Biella, Ponderano, I-13875 Biella, Italy.
Article Synopsis
- Fluoropyrimidines (FP) are a key chemotherapy for colorectal cancer (CRC) but can lead to underreported heart damage, known as FP-induced cardiotoxicity (FIC).
- A study monitored 129 CRC patients for FIC, finding that 15.5% experienced symptoms like chest pain and dyspnoea, although most had no significant ECG changes.
- No specific risk factors were strongly linked to FIC, aside from alcohol consumption in females, and no effective circulating biomarkers were identified for predicting FIC, emphasizing the need for careful symptom monitoring during FP treatment.